Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy.
We describe a patient with sight threatening thyroid associated ophthalmopathy (TAO) who was successfully treated with infliximab, an anti-tumour necrosis factor (TNF)-a antibody.